Alliance Funded Drug Delivery System Shows Promise in Recent Clinical Study

BIND Biosciences, a company established by Alliance researchers from MIT and Harvard Medical School, published their first results of a clinical study indicating that their targeted nanotherapeutic (BIND-014) is well tolerated and capable of shrinking patient tumors. Read more

Delivering Nanoparticles to the Cell Nucleus

Nanoparticle Factories Churn Out Proteins - Could Manufacture Cancer Drugs at Tumor Sites

New Technique Detects Trace Levels of New Class of Cancer Biomarkers

Normalizing Tumor Blood Vessels Improves Delivery of Only the Smallest Nanomedicines

'Bed-Of-Nails' Breast Implant Deters Cancer Cells

'Nanobubbles' Plus Chemotherapy Equals Single-Cell Cancer Targeting

Enter your email below to receive news and updates:

Alliance Researchers Elected to Leading Scientific Organizations

Alliance researchers Joseph DeSimone, Ph.D. (Carolina CCNE) and Phillip Sharp, Ph.D. (Harvard-MIT CCNE) were recently elected to prominent scientific organizations. DeSimone has been elected into the National Academy of Sciences, one of the highest honors that a U.S. scientist or engineer can receive. Sharp has been chosen to serve as president-elect of AAAS. He will begin his one-year term as president in February 2013, at the close of the 179th AAAS Annual Meeting in Boston.

Read more Alliance in the News stories

NCI Initiates Public-Private Industry Partnership

Nanotechnology allows researchers to study cancer in its earliest stages of progression, enabling early detection and development of novel therapies to target the disease. Learn more about nanotechnology's impact on cancer

Learn more about potential uses for nanotechnology for diagnosing and treating cancer. Listen to the podcast series